Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study to assess safety and bleeding risk in cancer patients receiving dual treatment with Tyrosine kinase inhibitors of vascular endothelial growth factor receptor and factor Xa inhibitors

Next Previous
Search
Trial Profile

A retrospective study to assess safety and bleeding risk in cancer patients receiving dual treatment with Tyrosine kinase inhibitors of vascular endothelial growth factor receptor and factor Xa inhibitors

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Axitinib (Primary) ; Cabozantinib (Primary) ; Lenvatinib (Primary) ; Low molecular weight heparins (Primary) ; Pazopanib (Primary) ; Regorafenib (Primary) ; Rivaroxaban (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary) ; Tivozanib (Primary) ; Vandetanib (Primary)
  • Indications Cancer; Haemorrhage; Renal cell carcinoma; Thrombosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Jun 2020 New trial record
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top